[{"address1": "One Corporate Drive", "address2": "2nd Floor", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "800 466 6059", "website": "https://www.aligos.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-\u00df agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 70, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lawrence M. Blatt MBA, Ph.D.", "age": 63, "title": "CEO, President & Chairman of the Board", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 1006234, "exercisedValue": 0, "unexercisedValue": 228334}, {"maxAge": 1, "name": "Ms. Lesley Ann Calhoun CPA", "age": 59, "title": "Executive VP, CFO & COO", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 658230, "exercisedValue": 0, "unexercisedValue": 73311}, {"maxAge": 1, "name": "Dr. Julian A. Symons DPHIL", "age": 64, "title": "Executive VP & Chief Scientific Officer", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 677467, "exercisedValue": 0, "unexercisedValue": 52440}, {"maxAge": 1, "name": "Ms. Laura  Kavanaugh", "title": "VP & Head of Legal", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristina  Engeseth M.B.A.", "title": "Senior VP and Head of People & Culture", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sushmita M. Chanda DABT, Ph.D.", "age": 58, "title": "Executive Vice President & Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David B. Smith Ph.D.", "title": "Executive VP & Head of Chemical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tse-I  Lin Ph.D.", "title": "Senior VP of Early Compound Development & Belgian Site Head", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1768176000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 8.26, "open": 8.29, "dayLow": 7.94, "dayHigh": 8.6437, "regularMarketPreviousClose": 8.26, "regularMarketOpen": 8.29, "regularMarketDayLow": 7.94, "regularMarketDayHigh": 8.6437, "payoutRatio": 0.0, "beta": 2.645, "forwardPE": -1.1171582, "volume": 64783, "regularMarketVolume": 64783, "averageVolume": 77059, "averageVolume10days": 76110, "averageDailyVolume10Day": 76110, "bid": 6.11, "ask": 10.31, "bidSize": 2, "askSize": 2, "marketCap": 48859440, "fiftyTwoWeekLow": 3.76, "fiftyTwoWeekHigh": 34.37, "allTimeHigh": 937.75, "allTimeLow": 3.76, "priceToSalesTrailing12Months": 18.465397, "fiftyDayAverage": 9.2456, "twoHundredDayAverage": 8.2507, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -44171560, "profitMargins": 0.0, "floatShares": 3138388, "sharesOutstanding": 5353582, "sharesShort": 240691, "sharesShortPriorMonth": 226418, "sharesShortPreviousMonthDate": 1764288000, "dateShortInterest": 1767139200, "sharesPercentSharesOut": 0.039100002, "heldPercentInsiders": 0.10366, "heldPercentInstitutions": 0.53104, "shortRatio": 3.39, "shortPercentOfFloat": 0.045900002, "impliedSharesOutstanding": 6153582, "bookValue": 11.674, "priceToBook": 0.68014395, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -86462000, "trailingEps": -13.54, "forwardEps": -7.10732, "lastSplitFactor": "1:25", "lastSplitDate": 1724025600, "enterpriseToRevenue": -16.694, "enterpriseToEbitda": 0.515, "52WeekChange": -0.75554895, "SandP52WeekChange": 0.14799047, "quoteType": "EQUITY", "currentPrice": 7.94, "targetHighPrice": 175.0, "targetLowPrice": 20.0, "targetMeanPrice": 68.2, "targetMedianPrice": 50.0, "recommendationMean": 1.2, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 99096000, "totalCashPerShare": 16.104, "ebitda": -85820000, "totalDebt": 6065000, "quickRatio": 4.507, "currentRatio": 4.704, "totalRevenue": 2646000, "debtToEquity": 8.443, "revenuePerShare": 0.299, "returnOnAssets": -0.54704, "returnOnEquity": -1.4182401, "grossProfits": -65800000, "freeCashflow": -45352752, "operatingCashflow": -79161000, "revenueGrowth": -0.416, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -38.27395, "financialCurrency": "USD", "symbol": "ALGS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "Aligos Therapeutics, Inc.", "longName": "Aligos Therapeutics, Inc.", "priceEpsCurrentYear": -1.0464056, "fiftyDayAverageChange": -1.3055997, "fiftyDayAverageChangePercent": -0.14121309, "twoHundredDayAverageChange": -0.31069994, "twoHundredDayAverageChangePercent": -0.037657402, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-10-16", "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1768605553, "regularMarketTime": 1768597201, "exchange": "NCM", "messageBoardId": "finmb_581475891", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1602855000000, "postMarketChangePercent": -1.0075557, "postMarketPrice": 7.86, "postMarketChange": -0.07999992, "regularMarketChange": -0.32, "regularMarketDayRange": "7.94 - 8.6437", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 77059, "fiftyTwoWeekLowChange": 4.1800003, "fiftyTwoWeekLowChangePercent": 1.1117022, "fiftyTwoWeekRange": "3.76 - 34.37", "fiftyTwoWeekHighChange": -26.429998, "fiftyTwoWeekHighChangePercent": -0.76898456, "fiftyTwoWeekChangePercent": -75.55489, "earningsTimestamp": 1762435800, "earningsTimestampStart": 1762435800, "earningsTimestampEnd": 1762435800, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -13.54, "epsForward": -7.10732, "epsCurrentYear": -7.58788, "regularMarketChangePercent": -3.87409, "regularMarketPrice": 7.94, "displayName": "Aligos Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-01-17"}]